1. Home
  2. Stocks
  3. Caplipoint Share Price

Caplin Point Laboratories Share Price

Pharmaceuticals Mid Cap

₹2,021.70 +51.9 (2.63%)

05 Nov, 2024 22:17

SIP TrendupStart SIP in CAPLIPOINT

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹1,951
  • High
  • ₹2,038
  • 52 Week Low
  • ₹1,050
  • 52 Week High
  • ₹2,159
  • Open Price₹1,969
  • Previous Close₹1,970
  • Volume78,444

Investment Returns

  • Over 1 Month + 2.66%
  • Over 3 Month + 23.32%
  • Over 6 Month + 55.67%
  • Over 1 Year + 91.97%
SIP Lightning

Smart Investing Starts Here Start SIP with Caplin Point Laboratories for Steady Growth!

Caplin Point Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 32.2
  • PEG Ratio
  • 1.5
  • Market Cap Cr
  • 15,367
  • P/B Ratio
  • 6.8
  • Average True Range
  • 77.39
  • EPS
  • 37.2
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 5.71
  • RSI
  • 58.79
  • MFI
  • 68.27

Caplin Point Laboratories Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations185.64139.38132.83179.22173.66
Total Income From Operations185.64139.38132.83179.22173.66
P/L Before Interest, Excpt. Items & Tax96.7086.9374.46107.2297.22
P/L Before Exceptional Items & Tax96.6886.9174.43107.2097.19
P/L After Tax from Ordinary Activities72.5469.8855.4582.1076.27
Net Profit/Loss For the Period72.5469.8855.4582.1076.27
IndicatorMar 24Mar 23
Revenue From Operations [Gross]613.41520.62
Revenue From Operations [Net]613.41520.62
Total Operating Revenues625.09528.61
Total Revenue730.93627.61
Total Expenses365.19334.46
Profit/Loss Before Tax365.74293.15
Profit/Loss For The Period283.71234.26
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity111.01157.10
Net Cash Used In Investing Activity-118.94-86.67
Net Cash Used in Finance Activity-34.26-30.42
Net Inc/Dec In Cash And Equivalent-41.3841.01
Cash And Equivalent End Of Year80.64122.02
IndicatorMar 24Mar 23
Total Share Capital15.1915.18
Total Non-Current Liabilities12.8616.42
Total Current Liabilities119.30146.85
Total Capital And Liabilities1,522.311,303.18
Total Non-Current Assets819.21639.20
Total Current Assets703.10663.98
Total Assets1,522.311,303.18
Indicator20242023
EBIT Margin (%)58.5255.47
Return On Capital Employed (%)26.0725.36
Return On Equity (%)20.4020.55
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)183.03150.19
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations458.96453.22435.50410.06395.32
Total Income From Operations458.96453.22435.50410.06395.32
P/L Before Interest, Excpt. Items & Tax154.41146.12145.56146.07127.19
P/L Before Exceptional Items & Tax154.36145.97145.39145.89126.91
P/L After Tax from Ordinary Activities124.90121.17119.80116.03104.15
Net Profit/Loss For the Period124.90121.17119.80116.03104.15
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,676.781,453.82
Revenue From Operations [Net]1,676.781,453.82
Total Operating Revenues1,694.101,466.73
Total Revenue1,761.041,522.71
Total Expenses1,196.881,071.44
Profit/Loss Before Tax564.43451.35
Profit/Loss For The Period461.42376.99
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity318.39271.37
Net Cash Used In Investing Activity-320.04-217.58
Net Cash Used in Finance Activity-38.07-28.17
Net Inc/Dec In Cash And Equivalent-39.0126.80
Cash And Equivalent End Of Year138.55177.56
IndicatorMar 24Mar 23
Total Share Capital15.1915.18
Total Non-Current Liabilities20.0116.13
Total Current Liabilities331.28268.00
Total Capital And Liabilities2,698.122,191.40
Total Non-Current Assets805.20636.94
Total Current Assets1,892.921,554.46
Total Assets2,698.122,191.40
Indicator20242023
EBIT Margin (%)33.3430.82
Return On Capital Employed (%)23.8623.50
Return On Equity (%)20.3920.83
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)299.18241.46

Caplin Point Laboratories Technicals

EMA & SMA

Current Price
₹2,021.70
+ 51.9 (2.63%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹1,930.84
  • 50 Day
  • ₹1,878.74
  • 100 Day
  • ₹1,762.66
  • 200 Day
  • ₹1,586.59

Resistance and Support

2003.6 Pivot Speed
  • R3 2,143.15
  • R2 2,090.60
  • R1 2,056.15
  • S1 1,969.15
  • S2 1,916.60
  • S3 1,882.15

Is Caplin Point Laboratories Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Caplin Point Laboratories is a rapidly growing pharmaceutical company with a strong presence in Latin America, Francophone Africa, and expanding into regulated markets like the USA and EU. it specializes in manufacturing and distributing a wide range of pharmaceutical products. Caplin Point Labs. has an operating revenue of Rs. 1,757.74 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 33% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 32% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 79 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Caplin Point Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-07 Quarterly Results
2024-08-07 Quarterly Results & Final Dividend
2024-05-16 Audited Results & Interim Dividend
2024-02-09 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2024-05-31 INTERIM Rs.2.50 per share(125%)Interim Dividend
2023-06-09 INTERIM Rs.2.00 per share(100%)Interim Dividend
2022-05-24 INTERIM Rs.2.00 per share(100%)Interim Dividend
2021-05-19 INTERIM Rs.1.50 per share(75%)Interim Dividend

Caplin Point Laboratories F&O

Caplin Point Laboratories Shareholding Pattern

70.56%
1.62%
0.15%
3.71%
0%
17.12%
6.84%
  • NSE Symbol
  • CAPLIPOINT
  • BSE Symbol
  • 524742
  • Managing Director
  • Dr. Sridhar Ganesan
  • ISIN
  • INE475E01026

Caplin Point Laboratories FAQs

Caplin Point Laboratories share price is ₹2,021 As on 05 November, 2024 | 22:03

The Market Cap of Caplin Point Laboratories is ₹15367.3 Cr As on 05 November, 2024 | 22:03

The P/E ratio of Caplin Point Laboratories is 32.2 As on 05 November, 2024 | 22:03

The PB ratio of Caplin Point Laboratories is 6.8 As on 05 November, 2024 | 22:03

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.